bioRxivCancer BiologyPreprint
Rapid generation of precision preclinical cancer models using regulatable in vivo base editing
A. Katti, M. Foronda, J. Zimmermann, M. P. Zafra, S. Goswami, E. E. Gardner, B. J. Diaz, J. M. Simon, A. Wuest, W. Luan, M. T. C. Fernandez, A. P. Kadina, J. A. Walker, K. Holden, F. J. Sanchez-Rivera, S. W. Lowe, L. E. Dow
Abstract
Single nucleotide variants (SNVs) comprise the majority of cancer-associated genetic changes and can have diverse effects on protein function. Despite a comprehensive catalogue of SNVs across human cancers, little is known about their impact on tumor initiation and progression. To enable the functional interrogation of cancer-associated SNVs, we developed a murine system for temporal and regulatable in vivo cytosine base editing (iBE). The iBE mice show robust, doxycycline-dependent expression across a broad range of tissues with no evidence of DNA or RNA off-target effects. Transient iBE induction drives efficient creation of individual or multiple SNVs in intestinal, lung, and pancreatic organoids, while temporal iBE regulation allows controlled sequential genome editing. Moreover, in situ delivery of plasmid-based or synthetic sgRNAs to target tissues facilitates the simple and rapid generation of pre-clinical cancer models. Overall, iBE is a powerful in vivo platform to define and interrogate the genetic drivers of cancer.
- organism: mouse
- assay: CRISPR screen
- research focus: cancer & tumor microenvironment
- research focus: cell type annotation
- research focus: gene regulatory network inference
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Multiplexed in vivo base editing identifies functional gene-variant-context interactions
Jonuelle Acosta, Grace A. Johnson, … Francisco J. Sánchez Rivera·bioRxiv·Feb 23, 2025
- Direct delivery of stabilized Cas-embedded base editors achieves efficient and accurate editing of clinically relevant targets
J. M. Lee, J. Zeng, … C. A. Schiffer·bioRxiv·Feb 8, 2024
- Direct genome editing of patient-derived xenografts using CRISPR-Cas9 enables rapid in vivo functional genomics
C. H. Hulton, E. A. Costa, … J. T. Poirier·bioRxiv·Mar 26, 2019
- Base editing generates substantial off-target single nucleotide variants
- ObLiGaRe doxycycline Inducible (ODIn) Cas9 system driving pre-clinical drug discovery, from design to cancer treatment
Anders Lundin, Michelle J. Porritt, … Marcello Maresca·bioRxiv·Apr 6, 2020
- High-precision CRISPR-Cas9 base editors with minimized bystander and off-target mutations
Jason M. Gehrke, Oliver Cervantes, … J. Keith Joung·bioRxiv·Mar 1, 2018